The estimated Net Worth of Dolca Thomas is at least $44.2 Tysiąc dollars as of 18 August 2020. Dr Thomas owns over 15,000 units of Equillium Inc stock worth over $14,462 and over the last 5 years he sold EQ stock worth over $29,700.
Dr has made over 3 trades of the Equillium Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of EQ stock worth $356,550 on 18 August 2020.
The largest trade he's ever made was exercising 15,000 units of Equillium Inc stock on 18 August 2020 worth over $356,550. On average, Dr trades about 3,812 units every 30 days since 2019. As of 18 August 2020 he still owns at least 16,826 units of Equillium Inc stock.
You can see the complete history of Dr Thomas stock trades at the bottom of the page.
Dr. Dolca Thomas M.D. is the Exec. VP of R&D and Chief Medical Officer at Equillium Inc.
Dr D is 50, he's been the Exec. VP of R&D and Chief Medical Officer of Equillium Inc since . There are 9 older and 6 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.
Dolca's mailing address filed with the SEC is C/O ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, CA, 94070.
Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski oraz Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Equillium Inc executives and other stock owners filed with the SEC include: